In the past decade, CAR-T therapy has made significant advances in hematological malignancies, demonstrating the vast potential of engineered immune cell therapies. However, traditional ex vivo CAR-T still requires individualized production processes, involving several stages such as cell collection, ex vivo genetic modification, cell expansion, quality control, transportation, and reinfusion. This complex workflow leads to longer treatment durations, higher manufacturing costs, and significant supply chain difficulties.
The emergence of in vivo CAR-T offers a new solution to the industry challenges associated with conventional CAR-T. As a key innovation at the intersection of cell therapy, RNA therapeutics, delivery technologies, and genetic engineering, in vivo CAR-T uses delivery systems like viral vectors and lipid nanoparticles to induce immune cells to express chimeric antigen receptors (CARs) within the body, enabling “in vivo engineering” of therapeutic cells. This approach has the potential to transform CAR-T therapy from a highly personalized model into a more standardized and scalable platform-based model.
Under this context, Frost & Sullivan, in collaboration with Cytiva, has jointly prepared and officially released the In Vivo CAR-T Industry Blue Book. The Blue Book provides a comprehensive overview of the industry’s development background, technical approaches, clinical progress, industrialization challenges, and future trends. Its purpose is to provide industry stakeholders, academic researchers, investors, and clinical professionals with a systematic perspective and reference.
Over the past decade, CAR-T therapy has achieved remarkable breakthroughs in hematological malignancies, validating the transformative potential of engineered immune cell therapies. However, conventional ex vivo CAR-T therapies still rely on individualized manufacturing processes, which involve multiple steps including cell collection, ex vivo genetic modification, cell expansion, quality control, transportation, and reinfusion. This complex workflow results in prolonged treatment timelines, high manufacturing costs, and significant supply chain challenges.
The emergence of in vivo CAR-T has introduced a promising new approach to addressing the limitations of conventional CAR-T therapies. As an important innovation at the intersection of cell therapy, RNA therapeutics, delivery technologies, and genetic engineering, in vivo CAR-T utilizes delivery systems such as viral vectors and lipid nanoparticles (LNPs) to induce immune cells to express chimeric antigen receptors (CARs) directly within the body, enabling “in vivo engineering” of therapeutic cells. This approach has the potential to transform CAR-T therapy from a highly individualized treatment paradigm into a more standardized and scalable platform-based model.
Against this backdrop, Frost & Sullivan (hereinafter referred to as “F&S”), in collaboration with Cytiva, has jointly prepared and officially released the In Vivo CAR-T Industry Blue Book. The Blue Book provides a comprehensive review of the industry’s development background, technological approaches, clinical translation progress, industrialization challenges, and future trends. It aims to offer industry participants, academic researchers, investors, and clinical professionals a systematic perspective and reference.
If you have further research needs regarding the Chinese Life Science market, please contact us:
Mr. Mao Frost & Sullivan
E-mail: fred.mao@frostchina.com
